Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.16
PLX's Cash to Debt is ranked higher than
58% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. PLX: 1.16 )
PLX' s 10-Year Cash to Debt Range
Min: 1.16   Max: No Debt
Current: 1.16

Equity to Asset -0.33
PLX's Equity to Asset is ranked lower than
52% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PLX: -0.33 )
PLX' s 10-Year Equity to Asset Range
Min: -0.5   Max: 0.8
Current: -0.33

-0.5
0.8
F-Score: 2
Z-Score: -1.71
M-Score: -2.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -235.53
PLX's Operating margin (%) is ranked higher than
64% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. PLX: -235.53 )
PLX' s 10-Year Operating margin (%) Range
Min: -8239.43   Max: -14.61
Current: -235.53

-8239.43
-14.61
Net-margin (%) -241.38
PLX's Net-margin (%) is ranked higher than
63% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. PLX: -241.38 )
PLX' s 10-Year Net-margin (%) Range
Min: -8103.09   Max: -14.27
Current: -241.38

-8103.09
-14.27
ROA (%) -24.52
PLX's ROA (%) is ranked higher than
69% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. PLX: -24.52 )
PLX' s 10-Year ROA (%) Range
Min: -427.74   Max: 1.8
Current: -24.52

-427.74
1.8
ROC (Joel Greenblatt) (%) -197.77
PLX's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. PLX: -197.77 )
PLX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -758.19   Max: -0.68
Current: -197.77

-758.19
-0.68
Revenue Growth (%) 14.50
PLX's Revenue Growth (%) is ranked higher than
87% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. PLX: 14.50 )
PLX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 236.2
Current: 14.5

0
236.2
EBITDA Growth (%) -7.60
PLX's EBITDA Growth (%) is ranked higher than
76% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. PLX: -7.60 )
PLX' s 10-Year EBITDA Growth (%) Range
Min: -53.6   Max: 84.2
Current: -7.6

-53.6
84.2
EPS Growth (%) -5.90
PLX's EPS Growth (%) is ranked higher than
80% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. PLX: -5.90 )
PLX' s 10-Year EPS Growth (%) Range
Min: -49.7   Max: 54.6
Current: -5.9

-49.7
54.6
» PLX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

PLX Guru Trades in Q2 2013

Jean-Marie Eveillard 500,000 sh (unchged)
Manning & Napier Advisors, Inc 159,710 sh (-88.85%)
» More
Q3 2013

PLX Guru Trades in Q3 2013

Jean-Marie Eveillard 500,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
» More
Q4 2013

PLX Guru Trades in Q4 2013

Jean-Marie Eveillard 700,000 sh (+40%)
» More
Q1 2014

PLX Guru Trades in Q1 2014

Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PLX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out 0.01%$3.85 - $5.26 $ 3.49-25%0
Jean-Marie Eveillard 2013-12-31 Add 40%$3.72 - $4.52 $ 3.49-17%700000
Jean-Marie Eveillard 2013-03-31 Reduce -23.08%$5.03 - $6.15 $ 3.49-37%500000
Jean-Marie Eveillard 2012-06-30 New Buy0.01%$5.57 - $7.27 $ 3.49-46%650000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 21.60
PLX's P/S is ranked higher than
71% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. PLX: 21.60 )
PLX' s 10-Year P/S Range
Min: 11.07   Max: 748
Current: 21.6

11.07
748
EV-to-EBIT -10.62
PLX's EV-to-EBIT is ranked higher than
72% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PLX: -10.62 )
PLX' s 10-Year EV-to-EBIT Range
Min: 44.9   Max: 58
Current: -10.62

44.9
58
Current Ratio 3.31
PLX's Current Ratio is ranked higher than
70% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. PLX: 3.31 )
PLX' s 10-Year Current Ratio Range
Min: 1.72   Max: 72.77
Current: 3.31

1.72
72.77
Quick Ratio 3.06
PLX's Quick Ratio is ranked higher than
70% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. PLX: 3.06 )
PLX' s 10-Year Quick Ratio Range
Min: 1.45   Max: 72.77
Current: 3.06

1.45
72.77

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.50
PLX's Price/Median PS Value is ranked higher than
95% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. PLX: 0.50 )
PLX' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 16.4
Current: 0.5

0.01
16.4
Forward Rate of Return (Yacktman) -20.19
PLX's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. PLX: -20.19 )
PLX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.8   Max: 38.3
Current: -20.19

-24.8
38.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PBD.Germany
Protalix BioTherapeutics, Inc. was originally formed as an Embassy Acquisition Corp., a Florida corporation, in November 2005 and changed its name to Orthodontix, Inc., in April, 1992. On December 31, 2006, it acquired, through a merger with its wholly-owned subsidiary, Protalix Acquisition Co. Ltd., all of the outstanding shares of Protalix Ltd., in exchange for shares of its common stock. As a result, Protalix Ltd. is now its wholly-owned subsidiary. In connection with the merger, it completed a one-for-ten reverse stock split and on February 26, 2007, it changed its name to Protalix BioTherapeutics, Inc. The Company and its wholly-owned subsidiary, Protalix Ltd. operate as biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx protein expression system or ProCellEx. The Company's product development candidate is prGCD for the treatment of Gaucher disease, which the Company is developing using its ProCellEx protein expression system. Using its ProCellEx system, it is developing a pipeline of proprietary and biosimilar or 'generic' versions of recombinant therapeutic proteins based on its plant cell-based expression technology that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. The Company's initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the fields in which it operates is intense and expected to increase. ProCellEx(tm) is its trademark. The testing, manufacture, distribution, advertising and marketing of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.
» More Articles for AMEX:PLX

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: AXP, CRAY, PLX, KMB, ITW, CATM, CAR May 07 2012 
Protalix BioTherapeutics Inc Reports Operating Results (10-K) Feb 23 2011 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Nov 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Oct 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Sep 08 2010 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 05 2010 
Protalix BioTherapeutics Inc (PLX) CEO and President David Aviezer sells 244,238 Shares Oct 21 2009 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 150,000 Shares Oct 19 2009 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 03 2009 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
First-ever kosher prescription medication Jul 01 2014
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working... Jun 27 2014
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure Jun 27 2014
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working... Jun 27 2014
Protalix BioTherapeutics Announces New Data on ELELYSO(TM) (taliglucerase alfa) and Oral GCD to be... Jun 23 2014
Protalix Drug in Phase IIa Study for Gaucher Disease Jun 19 2014
Protalix (PLX) in Focus: Stock Adds 6.5% in Session Jun 19 2014
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Jun 18 2014
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme... Jun 18 2014
Protalix CEO David Aviezer to retire this year Jun 13 2014
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jun 13 2014
Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., Will Retire... Jun 13 2014
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events May 30 2014
Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher... May 30 2014
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences May 28 2014
Protalix has a conference call hosted by JPMorgan May 27 2014
Protalix announces Australian approval of Elelyso May 22 2014
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events May 22 2014
Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Australia for the Treatment of... May 22 2014
PROTALIX BIOTHERAPEUTICS, INC. Financials May 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide